[Clinical trial of febuprol, a new substance with choleretic activity. Study of efficacy and tolerability].
In a clinical trial, performed according to new criteria of the AMG (Arzneimittelgesetz) 1976, a new choleretic monosubstance 3-n-butoxy-1-phenoxy-2-propanol (code number: K 10.033, H 33, febuprol, Valbil) has been tested. The clinical investigations conducted on 712 healthy volunteers and patients within a period of 4 years showed that Valbil is an effective and safe drug. Besides the choleretic properties, febuprol has some additional spasmolytic and lipid lowering effects.
D000433:1-Propanol / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D002756:Cholagogues and Choleretics / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002764:Cholecystitis / Q000188:drug therapy; D004285:Dogs; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood; D010276:Parasympatholytics; D010647:Phenyl Ethers; D020005:Propanols; D011817:Rabbits; D051381:Rats; D012306:Risk
D002756:Cholagogues and Choleretics; D008055:Lipids; D010276:Parasympatholytics; D010647:Phenyl Ethers; D020005:Propanols; D000433:1-Propanol; C006281:febuprol
Klinische Prüfung von Febuprol, einer neuen Substanz mit choleretischer Wirkung. Prüfung der Wirksamkeit und Verträglichkeit.